Int J Biol Sci 2022; 18(4):1313-1327. doi:10.7150/ijbs.67892 This issue


Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma

Xiao-jie Liang1#, Xin-yu Song2#, Jia-lin Wu3#, Dan Liu2, Bing-yu Lin2, Hong-sheng Zhou1✉, Liang Wang4✉

1. Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
2. The First Clinical Medical College, Guangdong Medical University, Zhanjiang 524000, China.
3. Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
4. Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
#The first three authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License ( See for full terms and conditions.
Liang Xj, Song Xy, Wu Jl, Liu D, Lin By, Zhou Hs, Wang L. Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma. Int J Biol Sci 2022; 18(4):1313-1327. doi:10.7150/ijbs.67892. Available from

File import instruction


Graphic abstract

As the most common subtype of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL) is characterized by a huge degree of clinical and prognostic heterogeneity. Currently, there is an urgent need for highly specific and sensitive biomarkers to predict the therapeutic response of DLBCL and assess which patients can benefit from systemic chemotherapy to help develop more precise therapeutic regimens for DLBCL. Systems biology (holistic study of diseases) is more comprehensive in quantifying and identifying biomarkers, helps addressing major biological problems, and possesses high accuracy and sensitivity. In this article, we provide an overview of research advances in DLBCL prognostic biomarkers made using the multi-omics approach of genomics, transcriptomics, epigenetics, proteomics, metabonomics, radiomics, and the currently developing single-cell technologies.

Keywords: Diffuse large B cell lymphoma, Prognosis, Precision medicine, Systems biology, Biomarkers